Objectives: This study aimed to investigate the role of T-cell imbalance in the pathogenesis of systemic lupus erythematosus (SLE), the role of Ubiquitin-binding enzyme 2N (UBC13) in the treatment of SLE.
Methods: Mice in the model group were intraperitoneally injected with normal saline. The UBC13 group was administered UBC13 recombinant protein, and the dexamethasone (DXM) group was treated with DXM for 8 weeks. Serum anti-dsDNA and ANA levels were quantified via ELISA. Histopathological changes were analyzed using H&E staining. Splenic mRNA expression of inflammatory cytokines and transcription factors was analyzed using qRT-PCR. Flow cytometry was used characterize Th1, Th2 and Treg cells populations, while western blotting was used to detect STAT3 and NF-κB signalling pathway-related proteins in thymic lysates.
Results: UBC13 administration ameliorated splenic hyperplasia and attenuated tissue damage in MRL/lpr mice, accompanied by a reduction in serum anti-dsDNA and ANA titers. Proinflammatory cytokine production, was suppressed following UBC13 intervention. Concurrently, UBC13 restored Th1/Th2 cell equilibrium and enhanced Treg cell suppressive function. Mechanistically, UBC13 inhibited NF-κB pathway activation and suppressed STAT3 phosphorylation.
Conclusion: UBC13 restores the homeostasis and function of Th1/Th2 and Treg cell through suppression of STAT3 and the NF-κB signaling pathway activation, thereby mitigating SLE-induced organ damage.
{"title":"Recombinant Protein UBC13 Improves Tissue Injury of MRL/Lpr Mice by Alleviating Th1/Th2 Immune Imbalance.","authors":"Mengchen Qi, Qian Li, Bingyao Ren, Ling Guo, Likang Zhang, Yulong Yang, Jiali Tao, Bin Sun, Junbing Jiang","doi":"10.1080/08820139.2025.2509086","DOIUrl":"10.1080/08820139.2025.2509086","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the role of T-cell imbalance in the pathogenesis of systemic lupus erythematosus (SLE), the role of Ubiquitin-binding enzyme 2N (UBC13) in the treatment of SLE.</p><p><strong>Methods: </strong>Mice in the model group were intraperitoneally injected with normal saline. The UBC13 group was administered UBC13 recombinant protein, and the dexamethasone (DXM) group was treated with DXM for 8 weeks. Serum anti-dsDNA and ANA levels were quantified via ELISA. Histopathological changes were analyzed using H&E staining. Splenic mRNA expression of inflammatory cytokines and transcription factors was analyzed using qRT-PCR. Flow cytometry was used characterize Th1, Th2 and Treg cells populations, while western blotting was used to detect STAT3 and NF-κB signalling pathway-related proteins in thymic lysates.</p><p><strong>Results: </strong>UBC13 administration ameliorated splenic hyperplasia and attenuated tissue damage in MRL/lpr mice, accompanied by a reduction in serum anti-dsDNA and ANA titers. Proinflammatory cytokine production, was suppressed following UBC13 intervention. Concurrently, UBC13 restored Th1/Th2 cell equilibrium and enhanced Treg cell suppressive function. Mechanistically, UBC13 inhibited NF-κB pathway activation and suppressed STAT3 phosphorylation.</p><p><strong>Conclusion: </strong>UBC13 restores the homeostasis and function of Th1/Th2 and Treg cell through suppression of STAT3 and the NF-κB signaling pathway activation, thereby mitigating SLE-induced organ damage.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"1064-1080"},"PeriodicalIF":2.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Osteoblasts, derived from mesenchymal stem cells (MSCs) in the bone marrow, are responsible for bone formation. Osteoblast differentiation is orchestrated by a spectrum of biological signals, with immune-derived components serving as indispensable regulators in this network. Dysfunctional osteoblast differentiation underlies bone-related pathologies such as osteoarthritis, rheumatoid arthritis, and osteoporosis, where immune dysregulation drives inflammatory cascades that disrupt the osteoblast-osteoclast equilibrium. This bidirectional crosstalk has propelled the emergence of osteoimmunology as a pivotal discipline.
Methods: By analyzing immune cells and cytokines in the immune microenvironment, we synthesize evidence on their roles in regulating osteoblast differentiation, with focus on inflammatory bone disorders, particularly in osteoarthritis.
Results: Thus, bone growth, development, and healing are intrinsically coupled with the dynamics of the immune microenvironment, which contributes to subchondral bone sclerosis and disease progression in osteoarthritis. Therefore, targeting immune-osteoblast crosstalk offers therapeutic potential for bone pathologies.
Conclusion: This review consolidates recent advances in understanding how the immune microenvironment impacts osteoblast differentiation, aiming to provide novel insights for clinical strategies targeting bone repair and disease mitigation.
{"title":"The Role of the Immune Microenvironment on Osteoblast Differentiation.","authors":"Mengtao Wang, Zhicheng Cao, Wenhui Hu, Zhiwen Dong, Yufeng Wang, Changyan Ma, Cheng Tang","doi":"10.1080/08820139.2025.2527246","DOIUrl":"10.1080/08820139.2025.2527246","url":null,"abstract":"<p><strong>Background: </strong>Osteoblasts, derived from mesenchymal stem cells (MSCs) in the bone marrow, are responsible for bone formation. Osteoblast differentiation is orchestrated by a spectrum of biological signals, with immune-derived components serving as indispensable regulators in this network. Dysfunctional osteoblast differentiation underlies bone-related pathologies such as osteoarthritis, rheumatoid arthritis, and osteoporosis, where immune dysregulation drives inflammatory cascades that disrupt the osteoblast-osteoclast equilibrium. This bidirectional crosstalk has propelled the emergence of osteoimmunology as a pivotal discipline.</p><p><strong>Methods: </strong>By analyzing immune cells and cytokines in the immune microenvironment, we synthesize evidence on their roles in regulating osteoblast differentiation, with focus on inflammatory bone disorders, particularly in osteoarthritis.</p><p><strong>Results: </strong>Thus, bone growth, development, and healing are intrinsically coupled with the dynamics of the immune microenvironment, which contributes to subchondral bone sclerosis and disease progression in osteoarthritis. Therefore, targeting immune-osteoblast crosstalk offers therapeutic potential for bone pathologies.</p><p><strong>Conclusion: </strong>This review consolidates recent advances in understanding how the immune microenvironment impacts osteoblast differentiation, aiming to provide novel insights for clinical strategies targeting bone repair and disease mitigation.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"962-1011"},"PeriodicalIF":2.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-06-19DOI: 10.1080/08820139.2025.2517364
Ziqi Xiong, Zhao Guan, Ainizati Hasimu, He Yu, Sen Zhou, Ayibaota Bahabayi, Qi Li, Guochong Wang, Zhonghui Zhang, Rui Kang, Pingzhang Wang, Chen Liu
Objective: This study aimed to explore the expression and clinical relevance of Ras homolog family member A (RhoA) in T cell subsets from patients with systemic lupus erythematosus (SLE).
Methods: Peripheral blood samples were obtained from newly diagnosed SLE patients and age- and sex-matched healthy controls. T cell subpopulations were analyzed by flow cytometry to quantify RhoA levels and associated cytotoxic markers, including granzyme B (GrB) and perforin (PFFN). Publicly available single-cell RNA sequencing (scRNA-seq) data were used to validate RhoA transcriptional patterns. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
Results: RhoA was unevenly distributed among circulating T cell populations, with the highest protein expression observed in CD8+ and effector memory subsets. RhoA+ T cells showed significantly higher GrB and PFN levels compared to their RhoA+ counterparts. In early-stage SLE, RhoA expression in T cells was significantly reduced compared to healthy individuals. However, a greater proportion of CD8+RhoA+ cells expressed GZMB in SLE patients. ROC analysis yielded area under the curve (AUC) values of 0.6720 for CD4+RhoA+ and 0.6635 for CD8+RhoA+ T cells.
Conclusion: RhoA+ T lymphocytes exhibit enhanced cytotoxic potential and may serve as early immunological markers for the identification of SLE.
{"title":"T Cells Expressing Ras Homolog Family Member a Display Enhanced Cytotoxicity but are Reduced in Lupus Peripheral Blood.","authors":"Ziqi Xiong, Zhao Guan, Ainizati Hasimu, He Yu, Sen Zhou, Ayibaota Bahabayi, Qi Li, Guochong Wang, Zhonghui Zhang, Rui Kang, Pingzhang Wang, Chen Liu","doi":"10.1080/08820139.2025.2517364","DOIUrl":"10.1080/08820139.2025.2517364","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the expression and clinical relevance of Ras homolog family member A (RhoA) in T cell subsets from patients with systemic lupus erythematosus (SLE).</p><p><strong>Methods: </strong>Peripheral blood samples were obtained from newly diagnosed SLE patients and age- and sex-matched healthy controls. T cell subpopulations were analyzed by flow cytometry to quantify RhoA levels and associated cytotoxic markers, including granzyme B (GrB) and perforin (PFFN). Publicly available single-cell RNA sequencing (scRNA-seq) data were used to validate RhoA transcriptional patterns. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>RhoA was unevenly distributed among circulating T cell populations, with the highest protein expression observed in CD8<sup>+</sup> and effector memory subsets. RhoA<sup>+</sup> T cells showed significantly higher GrB and PFN levels compared to their RhoA<sup>+</sup> counterparts. In early-stage SLE, RhoA expression in T cells was significantly reduced compared to healthy individuals. However, a greater proportion of CD8<sup>+</sup>RhoA<sup>+</sup> cells expressed GZMB in SLE patients. ROC analysis yielded area under the curve (AUC) values of 0.6720 for CD4<sup>+</sup>RhoA<sup>+</sup> and 0.6635 for CD8<sup>+</sup>RhoA<sup>+</sup> T cells.</p><p><strong>Conclusion: </strong>RhoA<sup>+</sup> T lymphocytes exhibit enhanced cytotoxic potential and may serve as early immunological markers for the identification of SLE.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"1138-1151"},"PeriodicalIF":2.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-06-26DOI: 10.1080/08820139.2025.2523315
Andreas Hiergeist, Sarah Miksch, Nicole Sabouret, Michaela Seeling, Katja Hohenberger, Joachim Gläsner, Falk Nimmerjahn, Markus Biburger, André Gessner
Background: Within decades of breeding, the common laboratory mouse strain C57BL/6 (B6) divided into various sub-strains with B6J and B6N being most frequently used. Recent studies showed significant genetic differences affecting several physiological, biochemical, and behavioral properties. In the immunology field, however, differences between these strains have barely been characterized and the necessity to use the adequate B6 sub-strain as experimental control appears largely unrecognized.
Methods: B6J and B6N mice were tested for a potential impact of their genetic background in various immunological models including experimental antibody-mediated immune-thrombocytopenia (ITP), B-cell depletion, K/BxN arthritis model, models of acute pneumonia, and dextran sulfate sodium (DSS)-induced colitis. Additionally, gut microbiota composition was analyzed in both healthy animals and in the context of DSS colitis.
Results: B6J and B6N mice performed equally in experimental antibody-mediated immune-thrombocytopenia and B-cell depletion. However, they revealed pronounced differences in the K/BxN arthritis model as well as in models of acute pneumonia and DSS-induced colitis. Furthermore, the B6 sub-strains demonstrated remarkable differences in gut microbiota composition that were detectable already in healthy animals and became augmented in the context of DSS colitis.
Conclusion: These findings mandate that researchers must specify and match B6 sub-strain backgrounds in immunological studies to ensure reproducibility and avoid misinterpretation of genetic modifications' effects.
{"title":"Genetic Differences Between N and J Sub-Strains of C57BL/6 Mice Critically Affect Multiple Immune Responses and Their Microbiota.","authors":"Andreas Hiergeist, Sarah Miksch, Nicole Sabouret, Michaela Seeling, Katja Hohenberger, Joachim Gläsner, Falk Nimmerjahn, Markus Biburger, André Gessner","doi":"10.1080/08820139.2025.2523315","DOIUrl":"10.1080/08820139.2025.2523315","url":null,"abstract":"<p><strong>Background: </strong>Within decades of breeding, the common laboratory mouse strain C57BL/6 (B6) divided into various sub-strains with B6J and B6N being most frequently used. Recent studies showed significant genetic differences affecting several physiological, biochemical, and behavioral properties. In the immunology field, however, differences between these strains have barely been characterized and the necessity to use the adequate B6 sub-strain as experimental control appears largely unrecognized.</p><p><strong>Methods: </strong>B6J and B6N mice were tested for a potential impact of their genetic background in various immunological models including experimental antibody-mediated immune-thrombocytopenia (ITP), B-cell depletion, K/BxN arthritis model, models of acute pneumonia, and dextran sulfate sodium (DSS)-induced colitis. Additionally, gut microbiota composition was analyzed in both healthy animals and in the context of DSS colitis.</p><p><strong>Results: </strong>B6J and B6N mice performed equally in experimental antibody-mediated immune-thrombocytopenia and B-cell depletion. However, they revealed pronounced differences in the K/BxN arthritis model as well as in models of acute pneumonia and DSS-induced colitis. Furthermore, the B6 sub-strains demonstrated remarkable differences in gut microbiota composition that were detectable already in healthy animals and became augmented in the context of DSS colitis.</p><p><strong>Conclusion: </strong>These findings mandate that researchers must specify and match B6 sub-strain backgrounds in immunological studies to ensure reproducibility and avoid misinterpretation of genetic modifications' effects.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"1167-1194"},"PeriodicalIF":2.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The aim of this study was to evaluate the possible role of lipopolysaccharide-binding protein (LBP) and interleukin 6 (IL-6) in the development of digital ulcers (DUs) in Systemic sclerosis (SSc).
Methods: 60 SSc patients were enrolled and tested for serum levels of LBP and IL-6. The development of DUs was assessed in a 12-month follow-up period.
Results: Median LBP and IL-6 were 107.445 ng/mL and 10.8 pg/mL whilst 33.3% patients had LBP ≥ 11995 ng/mL and 51.7% patients had IL-6 ≥ 12.5 pg/mL. DUs history were present in 41.7% SSc patients and at follow-up 23.3% patients developed new DUs. Baseline LBP (14105 ng/mL vs 10355 ng/mL, p < .001) and IL-6 (195 pg/mL vs 9.4 ng/mL, p < .001) were higher in SSc patients with new DUs. The ROC curves showed a good diagnostic accuracy for a cut-off of LBP ≥ 11995 ng/mL [AUC = 0.804 (95% CI = 0.656-0.951), p < .001] and for a cut-off of IL-6 ≥ 12.5 pg/mL [AUC = 0.897 (95% CI = 0.783-1.000), p < .001]. Free survival from new DUs was shorter in SSc patients with increased LBP (p < .001) or IL-6 (p = .003).
Conclusions: LPB or IL-6 could play a role in digital microvascular damage of SSc patients.
背景:本研究的目的是评估脂多糖结合蛋白(LBP)和白细胞介素6 (IL-6)在系统性硬化症(SSc)患者数字溃疡(DUs)发展中的可能作用。方法:选取60例SSc患者,检测血清LBP和IL-6水平。在12个月的随访期间评估DUs的发展情况。结果:中位LBP和IL-6分别为107.445 ng/mL和10.8 pg/mL, 33.3%的患者LBP≥11995 ng/mL, 51.7%的患者IL-6≥12.5 pg/mL。41.7%的SSc患者有DUs病史,随访时23.3%的患者出现新的DUs。基线LBP (14105 ng/mL vs 10355 ng/mL, p p p p p = 0.003)。结论:LPB或IL-6可能在SSc患者手指微血管损伤中起一定作用。
{"title":"Markers of Endotoxemia and Inflammation are Associated with Digital Ulcers in Systemic Sclerosis Patients.","authors":"Chiara Pellicano, Alessandra Oliva, Amalia Colalillo, Cristina Luceri, Antonietta Gigante, Claudio Maria Mastroianni, Daniela Tornese, Valeria Carnazzo, Valerio Basile, Edoardo Rosato, Umberto Basile","doi":"10.1080/08820139.2025.2478932","DOIUrl":"10.1080/08820139.2025.2478932","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the possible role of lipopolysaccharide-binding protein (LBP) and interleukin 6 (IL-6) in the development of digital ulcers (DUs) in Systemic sclerosis (SSc).</p><p><strong>Methods: </strong>60 SSc patients were enrolled and tested for serum levels of LBP and IL-6. The development of DUs was assessed in a 12-month follow-up period.</p><p><strong>Results: </strong>Median LBP and IL-6 were 107.445 ng/mL and 10.8 pg/mL whilst 33.3% patients had LBP ≥ 11995 ng/mL and 51.7% patients had IL-6 ≥ 12.5 pg/mL. DUs history were present in 41.7% SSc patients and at follow-up 23.3% patients developed new DUs. Baseline LBP (14105 ng/mL vs 10355 ng/mL, <i>p</i> < .001) and IL-6 (195 pg/mL vs 9.4 ng/mL, <i>p</i> < .001) were higher in SSc patients with new DUs. The ROC curves showed a good diagnostic accuracy for a cut-off of LBP ≥ 11995 ng/mL [AUC = 0.804 (95% CI = 0.656-0.951), <i>p</i> < .001] and for a cut-off of IL-6 ≥ 12.5 pg/mL [AUC = 0.897 (95% CI = 0.783-1.000), <i>p</i> < .001]. Free survival from new DUs was shorter in SSc patients with increased LBP (<i>p</i> < .001) or IL-6 (<i>p</i> = .003).</p><p><strong>Conclusions: </strong>LPB or IL-6 could play a role in digital microvascular damage of SSc patients.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"795-808"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: HOX transcript antisense intergenic RNA (HOTAIR) has been implicated in inflammation and vascular pathology, but its role in regulation of ADAM17 and sepsis-induced endothelial injury remains unclear.
Methods: LPS-treated human umbilical vein endothelial cells (HUVECs) modeled sepsis-induced endothelial injury, which were assessed via qRT-PCR, western blot and immunofluorescence. HOTAIR-knockout mice were treated with cecal ligation and perforation to establish sepsis model.
Results: LPS-stimulation increased expression of HOTAIR and ADAM17 and decreased miR-326 levels in HUVECs. HOTAIR-knockdown by antisense oligonucleotides (ASOs) decreased ADAM17, TNF-α production and NF-κB activities; it also alleviated endothelial inflammation, VE-cadherin integrity damage, apoptosis and barrier dysfunction, while miR-326 inhibition reversed these effects. MiR-326 inhibited TNF-α/NF-κB via targeting ADAM17. Further experiments demonstrated recombinant TNF-α reversed the inhibitory effect of HOTAIR-ASOs on LPS-triggered TNF-α/NF-κB activation and downstream endothelial injury, which were further mitigated by NF-κB or p38 MAPK inhibitors. In-vivo experiments in HOTAIR-knockout mice confirmed the role of HOTAIR/miR-326/ADAM17 in regulating NF-κB and p38 MAPK inflammation, with improved lung injury and survival following sepsis.
Discussion: The HOTAIR/miR-326/ADAM17 axis is a key regulator of inflammation, endothelial injury and barrier dysfunction during sepsis via modulation of TNF-α/NF-κB signaling, providing new insights into the mechanisms underlying endothelial injury in sepsis.
{"title":"Mechanistic Insights into HOTAIR-Driven ADAM17/NF-Κb Activation and Endothelial Dysfunction in LPS-Challenged HUVECs.","authors":"Junbing He, Zixuan Shao, Zhuoji Li, Yufu He, Jingqi Zhang, Haotian Zhong, Jiekai Li, Qinghua Liu, Yiming Shao","doi":"10.1080/08820139.2025.2503174","DOIUrl":"10.1080/08820139.2025.2503174","url":null,"abstract":"<p><strong>Introduction: </strong>HOX transcript antisense intergenic RNA (HOTAIR) has been implicated in inflammation and vascular pathology, but its role in regulation of ADAM17 and sepsis-induced endothelial injury remains unclear.</p><p><strong>Methods: </strong>LPS-treated human umbilical vein endothelial cells (HUVECs) modeled sepsis-induced endothelial injury, which were assessed via qRT-PCR, western blot and immunofluorescence. HOTAIR-knockout mice were treated with cecal ligation and perforation to establish sepsis model.</p><p><strong>Results: </strong>LPS-stimulation increased expression of HOTAIR and ADAM17 and decreased miR-326 levels in HUVECs. HOTAIR-knockdown by antisense oligonucleotides (ASOs) decreased ADAM17, TNF-α production and NF-κB activities; it also alleviated endothelial inflammation, VE-cadherin integrity damage, apoptosis and barrier dysfunction, while miR-326 inhibition reversed these effects. MiR-326 inhibited TNF-α/NF-κB via targeting ADAM17. Further experiments demonstrated recombinant TNF-α reversed the inhibitory effect of HOTAIR-ASOs on LPS-triggered TNF-α/NF-κB activation and downstream endothelial injury, which were further mitigated by NF-κB or p38 MAPK inhibitors. In-vivo experiments in HOTAIR-knockout mice confirmed the role of HOTAIR/miR-326/ADAM17 in regulating NF-κB and p38 MAPK inflammation, with improved lung injury and survival following sepsis.</p><p><strong>Discussion: </strong>The HOTAIR/miR-326/ADAM17 axis is a key regulator of inflammation, endothelial injury and barrier dysfunction during sepsis via modulation of TNF-α/NF-κB signaling, providing new insights into the mechanisms underlying endothelial injury in sepsis.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"867-893"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Sepsis is caused by an uncontrolled inflammatory response and immune dysfunction, with lung injury being the most common complication and one of the leading causes of death in clinically ill patients. Interleukin 37 (IL-37) is a multifunctional cytokine that plays a vital role in various pathophysiological processes, including inflammation, infection, and immunity.
Methods: The study involved both clinical and animal experiments (establishing an animal model of sepsis-induced lung injury). Firstly, 50 patients with sepsis-induced lung injury and 50 healthy controls were included. In addition, a more in-depth study was conducted using animal models.
Results: IL-37, IL-6, PCT, and CRP levels were significantly higher in the sepsis-induced lung injury group. Correlation analysis revealed that IL-37 significantly correlated with IL-6, PCT, and CRP levels. In animal experiments, IL-37 significantly attenuated CLP-induced pulmonary edema and cellular injury while reducing the levels of inflammatory factors IL-6 and TNF-α, as well as sepsis-related inflammatory markers PCT and CRP. Moreover, IL-37 significantly downregulated the expression levels of genes and proteins of apoptosis-related molecules Caspase-3 and Bax and pathway molecules TGF-β and Smad3.
Discussion: The TGF-β/Smad3 pathway is involved in the process of IL-37 inhibiting inflammatory response and ameliorating sepsis-induced lung injury.
{"title":"IL-37 Alleviates Sepsis-Induced Lung Injury by Inhibiting Inflammatory Response Through the TGF-β/Smad3 Pathway.","authors":"Yufang Guo, Feifei Deng, Yali Jiang, Guodong Cao, Yixin Zhang, Gaowu Liu, Mayinur Alimujiang, Mairhaba Ayati, Yufeng Chen, Lili Chen, Su Lv, Xueqin Dou","doi":"10.1080/08820139.2025.2495958","DOIUrl":"10.1080/08820139.2025.2495958","url":null,"abstract":"<p><strong>Introduction: </strong>Sepsis is caused by an uncontrolled inflammatory response and immune dysfunction, with lung injury being the most common complication and one of the leading causes of death in clinically ill patients. Interleukin 37 (IL-37) is a multifunctional cytokine that plays a vital role in various pathophysiological processes, including inflammation, infection, and immunity.</p><p><strong>Methods: </strong>The study involved both clinical and animal experiments (establishing an animal model of sepsis-induced lung injury). Firstly, 50 patients with sepsis-induced lung injury and 50 healthy controls were included. In addition, a more in-depth study was conducted using animal models.</p><p><strong>Results: </strong>IL-37, IL-6, PCT, and CRP levels were significantly higher in the sepsis-induced lung injury group. Correlation analysis revealed that IL-37 significantly correlated with IL-6, PCT, and CRP levels. In animal experiments, IL-37 significantly attenuated CLP-induced pulmonary edema and cellular injury while reducing the levels of inflammatory factors IL-6 and TNF-α, as well as sepsis-related inflammatory markers PCT and CRP. Moreover, IL-37 significantly downregulated the expression levels of genes and proteins of apoptosis-related molecules Caspase-3 and Bax and pathway molecules TGF-β and Smad3.</p><p><strong>Discussion: </strong>The TGF-β/Smad3 pathway is involved in the process of IL-37 inhibiting inflammatory response and ameliorating sepsis-induced lung injury.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"809-823"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Rutin, a dietary flavonoid, exhibits anti-inflammatory, antioxidant, and immunomodulatory properties. The underlying mechanism of protection of rutin against Aflatoxin B1 (AFB1)-induced immunotoxicity is not completely elucidated. This study investigated the protective effect of rutin against Aflatoxin B1 (AFB1)-induced immunotoxicity in male Wistar rats, supported by molecular docking and dynamics simulations.
Methods: Forty male Wistar rats were grouped into five: control (corn oil), AFB1 (0.75 mg/kg bwt), AFB1 (1.5 mg/kg bwt), rutin (50 mg/kg bwt), and AFB1 (1.5 mg/kg bwt) + Rutin (50 mg/kg bwt) orally for 30 days.
Results: AFB1 exposure increased (p < 0.05) oxidative and inflammatory markers, altered hematological indices, and caused histological damage in the spleen and bone marrow. Elevated indoleamine 2,3-dioxygenase (IDO) activity, reduced CD4+ T cells, and unchanged tryptophan 2,3-dioxygenase (TDO) activity were also observed. Docking revealed strong binding affinities for AFB1 (-9.5 kcal/mol), rutin (-9.7 kcal/mol), and AFB1-rutin (-10.4 kcal/mol) with IDO. Rutin co-treatment restored oxidative, inflammatory, and hematological indices, mitigated histological damage, and normalized CD4+ T cells and IDO activity, as supported by computational studies.
Discussion: The activities/expression of immunosuppressive indoleamine 2, 3-dioxygenase is mostly regulated by inflammation and oxidative stress. This study provides new insights into the mechanisms underlying the modulation of immunotoxicity of AFB1 by dietary rutin.
{"title":"Aflatoxin B<sub>1</sub> Instigated Redox Imbalance is Accompanied by Amplified Indoleamine 2,3-Dioxygenase/tryptophan Catabolism in the Spleen and Erythrocyte of Male Wistar Rats: Protective Influence of Dietary Rutin.","authors":"Azubuike Peter Ebokaiwe, Nworie Okoro, Doris Olachi Alilonu, Euslar Nnenna Onu, Jacinta Nkechi Obimma, ChinazomMartina Eze, Olusanya Olasehinde","doi":"10.1080/08820139.2025.2503171","DOIUrl":"10.1080/08820139.2025.2503171","url":null,"abstract":"<p><strong>Introduction: </strong>Rutin, a dietary flavonoid, exhibits anti-inflammatory, antioxidant, and immunomodulatory properties. The underlying mechanism of protection of rutin against Aflatoxin B1 (AFB1)-induced immunotoxicity is not completely elucidated. This study investigated the protective effect of rutin against Aflatoxin B1 (AFB1)-induced immunotoxicity in male Wistar rats, supported by molecular docking and dynamics simulations.</p><p><strong>Methods: </strong>Forty male Wistar rats were grouped into five: control (corn oil), AFB<sub>1</sub> (0.75 mg/kg bwt), AFB<sub>1</sub> (1.5 mg/kg bwt), rutin (50 mg/kg bwt), and AFB<sub>1</sub> (1.5 mg/kg bwt) + Rutin (50 mg/kg bwt) orally for 30 days.</p><p><strong>Results: </strong>AFB<sub>1</sub> exposure increased (<i>p</i> < 0.05) oxidative and inflammatory markers, altered hematological indices, and caused histological damage in the spleen and bone marrow. Elevated indoleamine 2,3-dioxygenase (IDO) activity, reduced CD4+ T cells, and unchanged tryptophan 2,3-dioxygenase (TDO) activity were also observed. Docking revealed strong binding affinities for AFB<sub>1</sub> (-9.5 kcal/mol), rutin (-9.7 kcal/mol), and AFB<sub>1</sub>-rutin (-10.4 kcal/mol) with IDO. Rutin co-treatment restored oxidative, inflammatory, and hematological indices, mitigated histological damage, and normalized CD4+ T cells and IDO activity, as supported by computational studies.</p><p><strong>Discussion: </strong>The activities/expression of immunosuppressive indoleamine 2, 3-dioxygenase is mostly regulated by inflammation and oxidative stress. This study provides new insights into the mechanisms underlying the modulation of immunotoxicity of AFB1 by dietary rutin.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"844-866"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-05-21DOI: 10.1080/08820139.2025.2503167
Ping Lu, Tianfeng Sun
Background: Following the bioinformatics predictions, this investigation delves into the function of FOXM1 in the phenotype of macrophages and inflammatory responses in alcoholic hepatitis (AH).
Methods: A mouse model of AH was generated using the Lieber-DeCarli method, and mouse Kupffer cells (KCs) were treated with lipopolysaccharide and ethanol. Expression of FOXM1 and S1PR1 in mouse liver tissues or KCs was determined using RT-qPCR, immunofluorescence, or western blot assays. Loss- or gain-of-function assays of FOXM1 and S1PR1 were performed, followed by histopathological staining of the liver tissues, examination of the inflammatory cytokines, and assessment of macrophage phenotype.
Results: FOXM1 exhibited heightened expression in the mouse liver tissues and KCs in AH models. Silencing FOXM1 reduced pathological injury, hepatic steatosis, alanine aminotransferase and aspartate aminotransferase levels, inflammatory cytokine production, and pro-inflammatory (M1) polarization markers of macrophages. This condition also alleviated M1 polarization of KCs in vitro. FOXM1 promoted transcription and expression of S1PR1 by binding to its promoter. The additional upregulation of S1PR1, in the presence of FOXM1, rescued M1 skewing of macrophages both in vitro and in vivo, thus aggravating inflammatory responses.
Conclusion: This study identifies that FOXM1-mediated transcriptional upregulation of S1PR1 promotes pro-inflammatory activation of macrophages and augments liver injury in AH.
{"title":"FOXM1 Enhances Transcription of S1PR1 and Promotes Pro-Inflammatory Activation of Kupffer Cells in Alcoholic Hepatitis.","authors":"Ping Lu, Tianfeng Sun","doi":"10.1080/08820139.2025.2503167","DOIUrl":"10.1080/08820139.2025.2503167","url":null,"abstract":"<p><strong>Background: </strong>Following the bioinformatics predictions, this investigation delves into the function of FOXM1 in the phenotype of macrophages and inflammatory responses in alcoholic hepatitis (AH).</p><p><strong>Methods: </strong>A mouse model of AH was generated using the Lieber-DeCarli method, and mouse Kupffer cells (KCs) were treated with lipopolysaccharide and ethanol. Expression of FOXM1 and S1PR1 in mouse liver tissues or KCs was determined using RT-qPCR, immunofluorescence, or western blot assays. Loss- or gain-of-function assays of FOXM1 and S1PR1 were performed, followed by histopathological staining of the liver tissues, examination of the inflammatory cytokines, and assessment of macrophage phenotype.</p><p><strong>Results: </strong>FOXM1 exhibited heightened expression in the mouse liver tissues and KCs in AH models. Silencing FOXM1 reduced pathological injury, hepatic steatosis, alanine aminotransferase and aspartate aminotransferase levels, inflammatory cytokine production, and pro-inflammatory (M1) polarization markers of macrophages. This condition also alleviated M1 polarization of KCs <i>in vitro</i>. FOXM1 promoted transcription and expression of S1PR1 by binding to its promoter. The additional upregulation of S1PR1, in the presence of FOXM1, rescued M1 skewing of macrophages both <i>in vitro</i> and <i>in vivo</i>, thus aggravating inflammatory responses.</p><p><strong>Conclusion: </strong>This study identifies that FOXM1-mediated transcriptional upregulation of S1PR1 promotes pro-inflammatory activation of macrophages and augments liver injury in AH.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"824-843"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Antibodies have long served as fundamental tools in disease diagnosis and surveillance. Their utility as biomarkers has expanded beyond infectious diseases to encompass a wide range of health conditions.
Objectives: This review aims to explore recent advancements in antibody biomarker discovery and their applications in diagnosing and monitoring diverse health conditions. It also examines the role of antibody surveillance in public health and epidemiological studies.
Methods: A comprehensive analysis of recent literature was conducted, focusing on studies that identify and characterize disease-specific antibodies. Particular attention was given to their relevance in autoimmune diseases, infections, cancers, and neurological disorders.
Content: The review highlights disease-specific antibody biomarkers and their clinical significance. It also discusses the utility and challenges of antibody-based surveillance in assessing disease prevalence, tracking immunity trends, and supporting One Health strategies.
Conclusions: Recent advancements in antibody biomarker discovery demonstrate significant potential in improving early diagnosis, personalized treatment, and population-level health management. Antibody surveillance continues to play a pivotal role in guiding public health responses and understanding disease dynamics.
{"title":"The Power of Antibodies: Advancing Biomarker-Based Disease Detection and Surveillance.","authors":"Woei Kean Ng, Gunasegran Thanusha, Pei Pei Chong, Candy Chuah","doi":"10.1080/08820139.2025.2492246","DOIUrl":"10.1080/08820139.2025.2492246","url":null,"abstract":"<p><strong>Background: </strong>Antibodies have long served as fundamental tools in disease diagnosis and surveillance. Their utility as biomarkers has expanded beyond infectious diseases to encompass a wide range of health conditions.</p><p><strong>Objectives: </strong>This review aims to explore recent advancements in antibody biomarker discovery and their applications in diagnosing and monitoring diverse health conditions. It also examines the role of antibody surveillance in public health and epidemiological studies.</p><p><strong>Methods: </strong>A comprehensive analysis of recent literature was conducted, focusing on studies that identify and characterize disease-specific antibodies. Particular attention was given to their relevance in autoimmune diseases, infections, cancers, and neurological disorders.</p><p><strong>Content: </strong>The review highlights disease-specific antibody biomarkers and their clinical significance. It also discusses the utility and challenges of antibody-based surveillance in assessing disease prevalence, tracking immunity trends, and supporting One Health strategies.</p><p><strong>Conclusions: </strong>Recent advancements in antibody biomarker discovery demonstrate significant potential in improving early diagnosis, personalized treatment, and population-level health management. Antibody surveillance continues to play a pivotal role in guiding public health responses and understanding disease dynamics.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"770-794"},"PeriodicalIF":2.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}